Philip James Wealth Management Reduces Organon & Co. Stock Position
Philip James Wealth Management LLC significantly reduced its stake in Organon & Co. by 48.4% in the fourth quarter, selling 214,942 shares and retaining only 0.09% of the company's outstanding shares. This move by the investment firm, which previously held 229,230 shares, signals potential concerns about Organon & Co.'s outlook given its competitive market challenges. Organon & Co., a Merck spin-off focused on women's health and biosimilars, has a market cap of $1.65 billion and is trading at $6.35 per share, down from a 52-week high of $14.70.
Philip James Wealth Mangement LLC Lowers Stock Position in Organon & Co. $OGN
Philip James Wealth Management LLC significantly cut its stake in Organon & Co. by 48.4% in the fourth quarter, reducing its holding to 229,230 shares valued at $1.64 million. This comes as Organon missed Q4 earnings expectations with $0.63 EPS against $0.73 expected and revenue slightly below estimates, alongside a 5.3% year-over-year revenue decline. Analyst sentiment remains bearish, with an average "Reduce" rating and a price target of $8.50.
Organon (NYSE: OGN) CFO granted 404,840 RSUs and boosts share holdings
Organon & Co.'s CFO, Matthew M. Walsh, reported significant equity compensation transactions, including the grant of 404,840 restricted stock units (RSUs) which will vest in three equal installments from 2027 to 2029. He also exercised earlier RSU awards from 2023 and 2025 into common stock, with some shares withheld for tax obligations. Following these transactions, Walsh directly holds 212,746 shares of Organon common stock.
Total debt per share of Organon & Co. – SWB:7XP
This article provides financial information for Organon & Co. (SWB:7XP), specifically focusing on its total debt per share. It appears to be a financial data snippet from TradingView, offering a snapshot of Period Value, Change, and Change % metrics for the company's debt per share.
Organon (OGN) interim manufacturing chief granted 125,208 RSUs and exercises awards
Organon & Co.'s interim Head of Manufacturing & Supply, Juliana Papa, was granted 125,208 Restricted Stock Units (RSUs) on March 31, 2026, which will vest in three equal installments by March 31, 2029. On the same date, Papa exercised previously granted RSUs, involving 6,378 and 10,073 units, and had shares withheld to cover tax obligations at $5.70 per share. Following these transactions, she directly holds 33,235.703 common shares and 20,148 unvested RSUs.
Organon (OGN) CMO receives 200,333 RSUs and exercises prior award
Organon & Co.'s Head of R&D and CMO, Juan Camilo Arjona Ferreira, was granted 200,333 Restricted Stock Units (RSUs) on March 31, 2026, vesting in three equal installments. On the same date, he exercised 13,431 RSUs from a previous grant, with 4,820 shares withheld for tax obligations. Following these transactions, he directly holds 30,047.477 shares of common stock and 200,333 RSUs.
Organon (OGN) HR chief granted 166,944 RSUs and nets new shares
Organon & Co.'s Chief Human Resources Officer, Aaron Falcione, received a grant of 166,944 Restricted Stock Units (RSUs) on March 31, 2026, which will vest in three equal installments by March 31, 2029. Additionally, previously granted RSUs from 2023 and 2025 vested, converting into 6,732 and 11,193 shares of common stock, with some shares withheld for tax obligations at $5.70 per share. These transactions reflect routine equity compensation and vesting schedules rather than discretionary market trading.
Organon (NYSE: OGN) EVP Daniel Karp receives 100,166 RSU grant and new shares
Organon & Co.'s Executive VP, Corporate Development, Daniel Karp, was granted 100,166 Restricted Stock Units (RSUs) that will vest in three equal annual installments starting March 31, 2027. Additionally, previously granted RSUs from 2023 and 2025 partially vested, converting into common shares, and some shares were withheld to cover tax obligations. These transactions reflect routine equity compensation and vesting, not open-market trading, with Karp directly holding 69,547.923 shares of Organon common stock afterward.
[Form 4] Organon & Co. Insider Trading Activity
Organon & Co.'s Chief Information Officer, Rachel A. Stahler, reported significant stock activity on March 31, 2026, primarily involving Restricted Stock Units (RSUs). She received a new grant of 183,639 RSUs, while previously granted RSUs from 2023 and 2025 vested and were converted into common shares. After accounting for tax withholdings, Stahler directly holds 116,105.292 shares of Organon common stock.
Organon (OGN) interim CEO awarded 333,889 RSUs, exercises RSUs and withholds shares for taxes
Organon & Co.'s interim CEO, Joseph T. Morrissey Jr., was granted 333,889 Restricted Stock Units (RSUs) on March 31, 2026, which will vest in three equal installments over the next three years. He also exercised 24,584 previously granted RSUs into common stock and had 7,005 shares withheld for tax obligations at $5.70 per share. Following these transactions, Morrissey directly holds 123,122.923 shares of Organon common stock and 333,889 unvested RSUs.
[Form 4] Organon & Co. Insider Trading Activity
Organon & Co. executive Vittorio Nisita reported routine equity compensation activity through a Form 4 filing. He received a grant of 125,208 Restricted Stock Units (RSUs) on March 31, 2026, which will vest in three equal installments. Additionally, portions of earlier RSU grants from 2023 and 2025 vested, converting into 13,000 shares of common stock, with 4,453 shares withheld for tax obligations.
[Form 4] Organon & Co. Insider Trading Activity
Organon & Co.'s Senior Vice President and Corporate Controller, Lynette Holzbaur, reported recent equity compensation activities. This includes new grants of Restricted Stock Units (RSUs) on March 31, 2026, and the vesting of earlier RSU awards. The transactions also involved tax withholdings in common stock, resulting in Holzbaur directly holding 26,402.427 shares of Organon common stock.
OGN SEC Filings - ORGANON & CO 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for ORGANON & CO (OGN) SEC filings, including annual 10-K reports, quarterly 10-Q earnings, 8-K material events, and insider trading forms. It offers detailed, regulatory insights into Organon's operations, focusing on Women’s Health, General Medicines, and biosimilars, and includes AI-powered summaries to clarify the significance of each document for investors and traders.
Organon (OGN) EVP gains shares via RSU vesting and tax withholding
Organon & Co.'s Executive VP, Corp. Dev., Daniel Karp, exercised 14,184 Restricted Stock Units (RSUs) which converted into common stock. To cover tax obligations, 4,446 shares were withheld at a reference price of $5.84. Following these transactions, Karp directly holds 57,153.923 shares of Organon common stock.
Organon (NYSE: OGN) leader nets shares after 5,762 RSUs vest
Organon & Co. executive Nisita Vittorio exercised 5,762 Restricted Stock Units (RSUs) into common stock, which is considered a routine equity compensation event rather than an open-market sale. A total of 1,974 shares were withheld to cover tax obligations at a price of $5.84 per share. Following these transactions, Vittorio directly holds 62,072.158 shares of Organon common stock, with the RSUs vesting in three equal installments through March 2027.
Organon (OGN) interim manufacturing chief exercises 7,979 RSUs, nets shares
Organon & Co.'s Interim Head of Manufacturing & Supply, Juliana Papa Drinane, exercised 7,979 Restricted Stock Units (RSUs) on March 29, 2026, converting them into common stock. After 2,733 shares were withheld for tax purposes at $5.84 per share, she now directly holds 22,420.703 Organon common shares, reflecting a routine compensation-related equity increase. This transaction did not involve any open-market buying or selling.
Organon (OGN) CMO nets more shares after 8,865 RSUs vest
Organon & Co.'s Head of R&D & CMO, Juan Camilo Arjona Ferreira, acquired 8,865 common shares from the vesting of restricted stock units (RSUs) on March 29, 2026. To cover tax obligations, 3,181 shares were withheld, resulting in a net increase in his direct holdings to 21,436.477 common shares. These transactions were part of his equity compensation and did not involve open-market sales or purchases.
[Form 4] Organon & Co. Insider Trading Activity
Organon & Co.'s General Counsel and Corporate Secretary, Kirke Weaver, reported insider trading activity via a Form 4 filing. Weaver exercised 7,757 restricted stock units (RSUs) into common shares and had 2,210 shares withheld for tax obligations at $5.84 per share. Following these transactions, Weaver directly holds 79,401.163 shares of Organon common stock.
Organon & Co stock hits 52-week low at $5.76
Organon & Co (OGN) stock recently hit a 52-week low of $5.76, reflecting a significant 61.11% decline over the past year. Despite this downturn, InvestingPro analysis suggests the stock is in oversold territory based on RSI and is undervalued compared to its Fair Value. The company has recently presented data for its VTAMA cream, licensed MIUDELLA, and completed an independent review that found no misconduct.
Organon & Co. (OGN) Is Gaining Attention: Key Information to Consider Before Investing
Organon (OGN) has seen a significant stock price drop, underperforming both the S&P 500 and its sector. Despite some positive revisions in quarterly earnings estimates, full-year and next-year forecasts show declines, leading to a Zacks Rank #5 (Strong Sell). The article suggests investors consider fundamental factors and valuation analysis while noting the potential for short-term underperformance.
Organon & Co. (OGN) is a trending stock: Facts to know before betting on it
Organon & Co. (OGN) has been a trending stock lately, and investors are advised to understand the underlying factors, such as its recent price performance and analyst ratings, before making investment decisions. The article highlights key metrics including the stock's price, valuation, earnings expectations, and potential risks and opportunities to provide a comprehensive overview.
Organon & Co. Hits New 52-Week Low
Organon & Co. (NYSE:OGN) shares reached a new 52-week low of $5.76 on Monday, closing at $5.84, amid analyst downgrades and concerns about the pharmaceutical company's financial performance. Spun off from Merck & Co. in 2021, the company has seen its stock decline over 50% from its initial trading price, with firms like Zacks Research and Wall Street Zen issuing "strong sell" and "hold" ratings, respectively. This highlights the ongoing challenges Organon faces in establishing itself as an independent entity.
Organon & Co Stock: Steady Healthcare Player with Growth Potential Amid Market Pressures
Organon & Co, spun off from Merck, is a healthcare company focusing on women's health and biosimilars, offering North American investors a stable dividend payer with growth potential. The stock appears undervalued based on its price-to-earnings ratio and analyst projections, with key products like VTAMA and strategic initiatives aimed at expanding market reach. Despite market pressures and risks like patent expirations, the company's defensive portfolio and focus on accessible therapies position it for resilience and long-term value.
Organon (OGN) Suffers a Larger Drop Than the General Market: Key Insights
Organon (OGN) recently closed down 3.47%, underperforming the broader S&P 500, Dow, and Nasdaq indices. Over the past month, the pharmaceutical company's stock has fallen 16.32%, significantly trailing the Medical sector and the S&P 500. Analysts project a decrease in upcoming quarterly earnings and revenue for Organon, leading to a Zacks Rank of #5 (Strong Sell).
Organon & Co. (NYSE:OGN) Receives Consensus Rating of "Reduce" from Brokerages
Organon & Co. (NYSE:OGN) has received a consensus "Reduce" rating from seven brokerages, with five analysts issuing a "sell" rating. The average 12-month price target is $8.50, significantly higher than its current trading price of $6.01. The company recently missed Q4 earnings and revenue estimates, showing a 5.3% year-over-year revenue decrease.
Vanguard disaggregates holdings; reports 0 shares of Organon (OGN)
Vanguard has filed an amended Schedule 13G/A for Organon (OGN), reporting 0 shares beneficially owned, representing 0% of the class. This change is due to an internal realignment on January 12, 2026, where certain Vanguard subsidiaries and business divisions will now report beneficial ownership separately. The filing clarifies that these subsidiaries will continue to pursue the same investment strategies as Vanguard previously did.
Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age
Organon has presented new data from a post-hoc sub-analysis of its Phase 3 ADORING 1 and ADORING 2 trials for VTAMA® (tapinarof) cream, 1%. The analysis demonstrated early and consistent skin clearance and itch improvement in atopic dermatitis patients as young as two years old. These findings will be presented at the 2026 American Academy of Dermatology Annual Meeting.
Is It Time To Reassess Organon (OGN) After Its Sharp Share Price Slide
Organon (OGN) shares have fallen sharply, with a 58.0% decline over the past year, leading to questions about its valuation. Despite the price slide, a Discounted Cash Flow (DCF) analysis suggests the stock is significantly undervalued by 89.7%, and its Price-to-Earnings (P/E) ratio is well below both industry averages and its proprietary "Fair Ratio." The article presents both bull and bear case narratives for Organon, with fair values ranging from US$5 to US$9 per share.
Organon & Co stock faces renewed scrutiny amid women's health sector shifts and pipeline updates
Organon & Co (US68622V1061), a pharmaceutical company focused on women's health with products like Nexplanon, is attracting investor interest due to pipeline developments in contraception and emerging therapies. The company emphasizes a strategy of high-margin, low-competition products and aims for steady revenue streams in a dynamic market. Despite competitive challenges from companies like Bayer and Pfizer, Organon's dedicated focus and strong efficacy profiles of its products position it as a stable investment for US investors seeking exposure to the women's health sector.
Organon & Co stock faces renewed scrutiny amid women's health sector shifts and pipeline updates
Organon & Co (US68622V1061) is attracting investor attention due to recent developments in women's health and contraception, highlighting its growth potential despite competitive pressures. The company, spun off from Merck, focuses on established products like Nexplanon and NuvaRing, alongside new pipeline candidates, positioning itself for steady revenue streams. This focus offers US investors exposure to a defensive segment, providing stability for concentrated portfolios amid market dynamics.
Organon sees opportunities in China's push for high-quality population development
Organon, a global healthcare company, identifies significant opportunities in China's focus on high-quality population development and a health-centered medical system. The company plans to leverage its expertise in women's health and chronic disease management to support China's initiatives, including building a fertility-friendly society and addressing population aging. China is Organon's second-largest market, and the company is deepening its local presence and expanding cooperation with local partners.
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
The article from MSN has not been provided, therefore a summary cannot be generated. This placeholder response indicates that Organon & Co. (OGN) is drawing investor interest, as suggested by the title.
Organon: A High Cash Yield Hidden Behind Patent Fatigue
Organon, a pharmaceutical company focusing on women's health, biosimilars, and established brands, is analyzed for its high cash yield despite patent fatigue and leverage. The article highlights the company's solid cash generation, strategic focus on debt reduction through divestitures and minimal dividends, and the importance of maintaining cash flow durability to navigate its significant 2028 debt maturity wall. Investors like Kahn Brothers Group are noted for seeing value in Organon's levered equity due to its substantial free cash flow, viewing it as a balance sheet repair story rather than a growth story.
Sio Capital's New Organon Investment: A Value Play in Women's Health - News and Statistics
Sio Capital Management has made a new investment in Organon, acquiring over 3.4 million shares valued at approximately $24.5 million. This investment, representing about four percent of the fund's reportable assets, positions Organon as a potential value play given its focus on women's health and biosimilar pharmaceuticals. Despite a recent decline in stock price, Organon reported $6.22 billion in revenue and $187 million in net income, and its significant adjusted EBITDA may support its operations amidst its debt.
Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6?
Sio Capital Management has made a new $24.53 million investment in Organon (NYSE:OGN), a pharmaceutical company whose stock has fallen 61% over the past year to $6.03. This new position represents 4% of Sio's assets under management and suggests a potential value play, despite Organon's recent struggles with declining revenue and profitability. Analysts believe that while Organon is not a growth stock, its strong adjusted EBITDA and focus on stabilizing operations could signal a turnaround for the financially challenged company.
Organon & Co. Hits New 52-Week Low at USD 6.16 Amidst Declining Performance
Organon & Co. (ORG) has reached a new 52-week low of USD 6.16, reflecting a challenging year with a 69.92% drop in its stock price, significantly underperforming the S&P 500. The company faces difficulties including a negative operating profit margin, low inventory turnover, and a 35.56% decline in net profit, alongside rising raw material costs. With a market capitalization of USD 1,650 million and a low P/E ratio, its financial metrics indicate below-par performance in both the short and long term.
Organon (OGN) Declines Sharply Compared to Overall Market: Key Information for Investors
Organon (OGN) stock dropped 2.5% in the latest trading session, underperforming the broader market. Analyst expectations project decreases in both EPS and revenue for the upcoming quarter and the full year, and the company currently holds a Zacks Rank of #5 (Strong Sell). Despite a low Forward P/E and PEG ratio compared to the industry, recent analyst estimate revisions for Organon have trended downward, indicating shifting expectations.
Gotham Asset Management LLC Buys 1,007,691 Shares of Organon & Co. $OGN
Gotham Asset Management LLC increased its stake in Organon & Co. (NYSE:OGN) by 37.2% in the third quarter, purchasing over 1 million additional shares, bringing its total ownership to approximately 1.43% of the company. This comes as Organon reported missed Q4 earnings and revenue estimates, with its stock trading near a one-year low. Analysts currently hold a "Reduce" rating for the stock, with an average price target of $8.50.
Organon & Co. Experiences Evaluation Revision Amidst Market Challenges and Performance Divergence
Organon & Co., a small-cap pharmaceutical company, has experienced a significant 57.8% decline over the past year, with its stock currently priced at $6.33. Technical indicators show a bearish sentiment, contrasting sharply with the S&P 500's 19.17% gain in the same period. This evaluation revision highlights the ongoing challenges faced by the company in a competitive market.
Organon Q3 Net Margin Squeeze Challenges Bullish Earnings Growth Narratives
Organon (OGN) recently released its Q3 2025 earnings, reporting revenue of US$1,602 million and EPS of US$0.62. The company faces a significant net margin squeeze, dropping from 20.3% to 8% over the past year, which has led to a weaker trailing EPS despite analyst forecasts for future growth. Consequently, the stock trades at a much lower P/E ratio compared to its industry and peers.
Royce & Associates LP Trims Position in Organon & Co. $OGN
Royce & Associates LP significantly reduced its stake in Organon & Co. (NYSE:OGN) by 92.5% in the third quarter, selling 696,419 shares and holding 56,505 shares valued at $603,000. This move aligns with a negative Street consensus for Organon, which has an average "Reduce" rating and an $8.50 price target from analysts. The company recently missed quarterly EPS estimates and announced a modest quarterly dividend of $0.02, reinforcing analyst concerns reflected in recent downgrades and reduced price targets.
Organon (OGN) CIO logs stock awards and tax withholding share disposals
Organon & Co.'s Chief Information Officer, Rachel A. Stahler, reported the acquisition of 23,178 and 6,540 shares of common stock at no cost, stemming from vested performance share units and dividend equivalents. To cover tax obligations, 8,475 shares at $7.17 and 2,240 shares at $7.23 were disposed of through share withholding, not open-market sales. Following these transactions, her direct ownership totals 98,310.292 shares.
Organon & Co. (OGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing at Organon & Co. (NYSE:OGN). The firm is encouraging investors who purchased Organon securities before November 3, 2022, and still hold them, to contact them to assist in the investigation. The goal is to recover investor capital and ensure corporate accountability.
Organon (OGN) HR chief gets stock awards, withholds shares for taxes
Organon & Co.'s Chief Human Resources Officer, Aaron Falcione, reported receiving equity compensation on February 27, 2026, including 23,805 and 6,717 shares from performance share units and related dividend equivalents. To cover tax obligations, he disposed of 8,705 shares at $7.17 and 2,301 shares at $7.23 through tax-withholding dispositions. Following these transactions, Falcione directly owns 84,109.071 shares of Organon common stock.
Organon (OGN) GC Weaver gets stock awards, shares withheld for tax
Organon & Co.'s General Counsel, Kirke Weaver, received stock-based compensation and engaged in related tax-withholding transactions. Weaver acquired 21,925 shares from performance share units and 6,186 shares from dividend equivalents, with an additional 1,832.163 shares added from prior dividend equivalents. To cover tax liabilities, 6,815 shares and 1,763 shares were disposed of, resulting in Weaver directly owning 73,854.163 common shares.
Organon & Co. (NYSE:OGN) Receives Average Rating of "Reduce" from Brokerages
Organon & Co. (NYSE:OGN) has received a consensus "Reduce" rating from seven research firms, with an average 12-month price target of $8.50. The company recently reported Q4 earnings of $0.63 EPS on revenue of $1.51 billion, missing analyst estimates, and announced a quarterly dividend of $0.02. Institutional investors own approximately 77.4% of the shares.
Vanguard Group Inc. Has $383.72 Million Position in Organon & Co. $OGN
Vanguard Group Inc. increased its stake in Organon & Co. (NYSE:OGN) by 11.3% in Q3, now owning 35,928,403 shares valued at approximately $383.72 million. Despite this significant institutional holding, analysts maintain a "Reduce" consensus rating with an average target price of $8.50, following recent downgrades and missed earnings expectations. Organon also announced a small quarterly dividend of $0.02, representing a 1.1% yield.
Organon Refocuses On Contraception With MIUDELLA Deal And JADA Exit
Organon (NYSE:OGN) has announced a strategic shift, securing exclusive global licensing for MIUDELLA, a new hormone-free copper IUD, and selling its JADA System for postpartum bleeding. This move aims to sharpen Organon's focus on its core women's health portfolio, particularly contraception, amidst a challenging financial landscape with previous stock declines and a recent net loss. Investors will be watching how these portfolio adjustments influence market share, earnings quality, and the company's competitive positioning against larger pharmaceutical players.
Organon (NYSE:OGN) - Stock Analysis
This report provides a comprehensive stock analysis of Organon (NYSE:OGN), a pharmaceutical company focusing on women's health. It covers the company's market capitalization, current share price, valuation, future growth prospects, past performance, financial health, dividends, management, and ownership. The analysis highlights key takeaways from different analyst perspectives, including potential for growth through new products and market expansion, as well as risks such as global pricing pressures and debt obligations.
Bronstein, Gewirtz & Grossman, LLC Encourages Organon & Co. (OGN) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is urging Organon & Co. (NYSE: OGN) stockholders who purchased securities before November 3, 2022, and still hold them, to engage in a securities investigation. The firm is investigating potential corporate wrongdoing by Organon and its officers/directors. Investors can assist the investigation at bgandg.com/OGN, and the firm operates on a contingency fee basis.
